Related Experiment Video
Updated: Jul 6, 2025

08:01
A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli
Published on: August 12, 2016
9.0K
Exploring Nutritional Influence on Blood Glucose Forecasting for Type 1 Diabetes Using Explainable AI
IEEE Journal of Biomedical and Health Informatics
|December 29, 2023
Summary
This study quantifies how meal factors influence blood glucose after eating in type 1 diabetes. Using AI, it identifies key nutritional determinants for better glucose control and artificial pancreas management.
Area of Science:
- Endocrinology and Metabolism
- Artificial Intelligence in Medicine
- Computational Biology
Background:
- Type 1 diabetes mellitus (T1DM) requires precise blood glucose management, often aided by artificial pancreas (AP) systems.
- Current AP systems struggle with postprandial glucose response (PGR) due to incomplete understanding of meal impacts.
- Accurate insulin dosing for meals necessitates better prediction of postprandial blood glucose levels (BGLs).
Purpose of the Study:
- To quantify the influence of meal-related factors on predicting BGLs at 15, 60, and 120 minutes post-meal.
- To utilize deep neural network (DNN) models for BGL prediction incorporating nutritional data.
- To enhance the interpretability of BGL prediction models using eXplainable Artificial Intelligence (XAI).
Main Methods:
- Developed DNN models to predict BGLs using preprandial glucose, insulin dose, and meal nutritional factors (energy, carbs, protein, lipids, fiber, GI, GL).
- Applied SHapley Additive exPlanations (SHAP) to assess the impact and contribution of each input feature on model predictions.
- Validated model performance and feature importance against clinical literature hypotheses.
Main Results:
- Identified specific meal components and their quantities significantly impacting BGLs at various postprandial time points.
- Quantified the contribution of each nutritional factor to BGL prediction accuracy using SHAP values.
- Demonstrated the effectiveness of DNNs and XAI in understanding complex PGR determinants.
Conclusions:
- Meal composition significantly influences postprandial glucose excursions in T1DM.
- XAI methods provide crucial insights into the factors driving BGL predictions, enhancing model transparency.
- Findings support the development of advanced decision-support tools and improved AP technology for T1DM management.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Diabetes: Management and Pharmacotherapy
285
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
285
Hormones Regulating Blood Glucose
3.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.4K
Glucagon-like Receptor Agonists
325
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
325
Hypoglycemia and Glucagon
264
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
264

